Creo Medical Group PLC Investor Presentation
12 10월 2023 - 3:00PM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
12 October 2023
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Investor Presentation
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
Creo will deliver a presentation providing an overview of the
Company at a hybrid event in London hosted by the UK Individual
Shareholders' Society (ShareSoc) on Thursday 19 October 2023 and
available to ShareSoc members via the link below:
https://www.sharesoc.org/sharesoc-walbrook-pr-healthcare-companies-hybrid-event-london-19-october-2023-5pm/
Craig Gulliford , Chief Executive Officer will deliver an
"in-person" presentation which will also be streamed live (and
recorded), allowing ShareSoc members to watch virtually. N o new
material information will be disclosed in the presentation.
An online presentation covering the Company's interim results
for the six months ended 30 June 2023, and presented on 12
September 2023 , is available for all investors on the Investor
Meet Company platform and can be accessed via this link:
https://www.investormeetcompany.com/investor/meeting/investor-presentation-421
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cavendish Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson (Sales)
Numis Securities Limited (Joint
Broker)
Freddie Barnfield / Duncan Monteith
/ Euan Brown +44 (0)20 7260 1000
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEALEFFFNDFFA
(END) Dow Jones Newswires
October 12, 2023 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Creo Medical (LSE:CREO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
